HIVID
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jun 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HIVID is an oral small-molecule antiretroviral approved in 1992 for HIV treatment. The drug's exact mechanism of action and pharmacologic class are not publicly detailed in available records. This product represents an early-generation HIV therapeutic from the nucleoside reverse transcriptase inhibitor (NRTI) era.
LOE Approaching
This product is approaching loss of exclusivity with minimal linked job openings, indicating a highly contracted team focused on transition and compliance.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection
225 enrolled
HIV Infections
A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection
528 enrolled
HIV Infections
Career Relevance
Joining HIVID represents a career risk given zero linked job openings and approaching loss of exclusivity. Opportunities are limited to transition management, regulatory maintenance, and legacy product stewardship rather than commercial growth.
Regulatory Affairs Specialist
Worked on HIVID at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.